Log In
Sunday 26th May 2019

MS cannabis treatment doubt

13th December 2012

Doubts have been raised over the use of cannabis extract in the treatment of multiple sclerosis.

A review of evidence in the December issue of Drug and Therapeutics Bulletin (DTB), published by BMJ Journals, on the first licensed preparation Sativex suggested it had limitations which made it difficult to identify the place of the product in clinical practice. However GW Pharmaceuticals, which makes of the drug, indicated the comments gave a misleading view and that the review writers appeared to have misunderstood important elements of trials.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2019